

Supplementary Materials: MRI Dynamically Evaluates the Therapeutic Effect of Recombinant Human MANF on Ischemia/Reperfusion Injury in Rats

Xian-Yun Wang, Meng-Meng Song, Si-Xing Bi, Yu-Jun Shen, Yu-Xian Shen and Yong-Qiang Yu




Figure S1. SDS-PAGE gel for detection of purified His-mesencephalic astrocyte-derived neurotrophic factor (MANF).




Figure S2. T2-weighted images of 5 brain slices (S1–S5) from a representative rat in edaravone group 1, 2, 3, 5, and 7 days after treatment. Rats were treated with tail vein infusion of edaravone at 3 mg/kg body weight twice: immediately and 30 min after reperfusion of middle cerebral artery occlusion (MCAO). This treatment schedule and dosage were based on the pharmacokinetic profile of edaravone supplied by the manufacturer. d: day.